甘露聚糖肽对反复呼吸道感染的临床疗效和免疫功能影响的系统评价

Clinical Ei cacy of Mannatide for Recurrent Respiratory Tract Infection and Its Inl uence on Immune Function: A Systematic Review

目的系统评价甘露聚糖肽对反复呼吸道感染的临床疗效及免疫功能的影响。方法计算机检索h e Cochrane Library(2013年第12期)、PubMed、EMbase、CNKI、CBM、VIP和WanFang Data,收集甘露聚糖肽预防或治疗反复呼吸道感染的随机对照试验(RCT),检索时限均为从建库至2013年12月。由2位研究者按照纳入与排除标准筛选文献,提取数据和评价纳入研究的方法学质量后,采用RevMan 5.1.0软件进行Meta分析。结果共纳入18个研究,1 481例患者。与安慰剂组相比,甘露聚糖肽组在总有效率、提升T细胞水平和提升抗体水平上具有明显优势,差异有统计学意义(P<0.05);与左旋咪唑组相比,甘露聚糖肽组在有效率和提升T细胞水平方面具有明显优势(P<0.05),但在提升抗体水平上与其相当,其差异无统计学意义。结论甘露聚糖肽可显著提高反复呼吸道感染的临床疗效和患者免疫功能。

Objective To evaluate clinical efficacy of mannatide for recurrent respiratory tract infection （RRTI） and its influence on immune function. Methods The Cochrane Library （Issue 12, 2013）, PubMed, EMbase, CNKI, CBM, VIP and WanFang Data were searched for the randomized controlled trials （RCTs） that investigated the clinical and immune effect of mannatide in RRTI from inception to December 2013. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data and evaluated the methodological quality of included studies. Then meta-analysis was performed using the software RevMan 5.1.0. Results A total of 18 studies involving 1 481 patients were included. The results of meta-analysis showed that compared with the placebo group, the mannatide group was superior in total effectiveness and improving the levels of T-lymphocyte subsets and antibody （P〈0.05）; compared with the levomisole group, the mannatide group was superior in total effectiveness and improving the level of T-lymphocyte subsets （P〈0.05）, but not in improveming antibody level. Conclusion Mannatide improves clinical efficacy in the treatment of RRTI and patients＇ immune function.